404 related articles for article (PubMed ID: 31406978)
1. Major Depressive Disorder (MDD) and Schizophrenia- Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review.
Mallet J; Gorwood P; Le Strat Y; Dubertret C
Int J Neuropsychopharmacol; 2019 Oct; 22(10):651-664. PubMed ID: 31406978
[TBL] [Abstract][Full Text] [Related]
2. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
Citrome L
Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action of cariprazine.
Stahl SM
CNS Spectr; 2016 Apr; 21(2):123-7. PubMed ID: 26956157
[TBL] [Abstract][Full Text] [Related]
4. Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia.
Keks N; Hope J; Schwartz D; McLennan H; Copolov D; Meadows G
CNS Drugs; 2020 May; 34(5):473-507. PubMed ID: 32246399
[TBL] [Abstract][Full Text] [Related]
5. The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders.
De Berardis D; Orsolini L; Iasevoli F; Prinzivalli E; de Bartolomeis A; Serroni N; Mazza M; Valchera A; Fornaro M; Vecchiotti R; Carano A; Sepede G; Vellante F; Matarazzo I; Pompili M; Perna G; Conti C; Segura-García C; Martinotti G; Di Giannantonio M
Curr Pharm Des; 2016; 22(33):5144-5162. PubMed ID: 27396597
[TBL] [Abstract][Full Text] [Related]
6. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2015 Sep; 69(9):978-97. PubMed ID: 26250067
[TBL] [Abstract][Full Text] [Related]
7. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
[TBL] [Abstract][Full Text] [Related]
8. Brexpiprazole for the Treatment of Schizophrenia and Major Depressive Disorder: A Comprehensive Review of Pharmacological Considerations in Clinical Practice.
Edinoff AN; Wu NW; Maxey BS; Ren AL; Leethy KN; Girma B; Odisho A; Kaye JS; Kaye AJ; Kaye AM; Kaye AD; Mychaskiw G; Viswanath O; Urits I
Psychopharmacol Bull; 2021 Mar; 51(2):69-95. PubMed ID: 34092824
[TBL] [Abstract][Full Text] [Related]
9. Brexpiprazole: a new dopamine D₂receptor partial agonist for the treatment of schizophrenia and major depressive disorder.
Citrome L
Drugs Today (Barc); 2015 Jul; 51(7):397-414. PubMed ID: 26261843
[TBL] [Abstract][Full Text] [Related]
10. The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies.
Weiss C; Weiller E; Baker RA; Duffy RA; Gwin KK; Zhang P; McQuade RD
Int Clin Psychopharmacol; 2018 Sep; 33(5):255-260. PubMed ID: 29878915
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of brexpiprazole: comparison with aripiprazole.
Stahl SM
CNS Spectr; 2016 Feb; 21(1):1-6. PubMed ID: 26899451
[TBL] [Abstract][Full Text] [Related]
12. High dose antipsychotic polypharmacy and dopamine partial agonists - time to rethink guidelines?
Reynolds GP
J Psychopharmacol; 2021 Sep; 35(9):1030-1036. PubMed ID: 34256637
[TBL] [Abstract][Full Text] [Related]
13. Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.
Girgis RR; Slifstein M; D'Souza D; Lee Y; Periclou A; Ghahramani P; Laszlovszky I; Durgam S; Adham N; Nabulsi N; Huang Y; Carson RE; Kiss B; Kapás M; Abi-Dargham A; Rakhit A
Psychopharmacology (Berl); 2016 Oct; 233(19-20):3503-12. PubMed ID: 27525990
[TBL] [Abstract][Full Text] [Related]
14. Brexpiprazole.
Markovic M; Gallipani A; Patel KH; Maroney M
Ann Pharmacother; 2017 Apr; 51(4):315-322. PubMed ID: 28228056
[TBL] [Abstract][Full Text] [Related]
15. [Cariprazine, a new type - dopamine D₃ receptor preferring - partial agonist atypical antipsychotic for the treatment of schizophrenia and the primary negative symptoms].
Laszlovszky I; Kiss B; Barabassy A; Kapas M; Nemeth G
Neuropsychopharmacol Hung; 2019 Sep; 21(3):103-118. PubMed ID: 31537751
[TBL] [Abstract][Full Text] [Related]
16. Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy.
Inoue A; Nakata Y
Jpn J Pharmacol; 2001 Aug; 86(4):376-80. PubMed ID: 11569610
[TBL] [Abstract][Full Text] [Related]
17. Discovery research and development history of the dopamine D
Kikuchi T; Maeda K; Suzuki M; Hirose T; Futamura T; McQuade RD
Neuropsychopharmacol Rep; 2021 Jun; 41(2):134-143. PubMed ID: 33960741
[TBL] [Abstract][Full Text] [Related]
18. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
Newman-Tancredi A
Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive brexpiprazole for the treatment of major depressive disorder.
Beyer JL; Weisler RH
Expert Opin Pharmacother; 2016 Dec; 17(17):2331-2339. PubMed ID: 27788337
[TBL] [Abstract][Full Text] [Related]
20. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.
Veselinović T; Paulzen M; Gründer G
Expert Rev Neurother; 2013 Nov; 13(11):1141-59. PubMed ID: 24175719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
